AQR Capital Management
PRCT icon

AQR Capital Management’s Procept Biorobotics PRCT Stock Holding History

AQR Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.36M Buy
370,455
+114,604
+45% +$2.87M ﹤0.01% 1682
2026
Q1 		$6.4M Buy
255,851
+212,793
+494% +$6M ﹤0.01% 1589
2025
Q4 		$1.35M Sell
43,058
-23,283
-35% -$772K ﹤0.01% 2374
2025
Q3 		$2.37M Buy
66,341
+12,887
+24% +$588K ﹤0.01% 1882
2025
Q2 		$3.08M Buy
53,454
+34,562
+183% +$1.95M ﹤0.01% 1541
2025
Q1 		$1.1M Buy
18,892
+1,286
+7% +$87.8K ﹤0.01% 1965
2024
Q4 		$1.42M Buy
17,606
+8,590
+95% +$734K ﹤0.01% 1703
2024
Q3 		$722K Buy
9,016
+3,877
+75% +$275K ﹤0.01% 2008
2024
Q2 		$314K Buy
+5,139
New +$306K ﹤0.01% 2248

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AQR Capital Management's PRCT Position: Q2 2026 in Review

AQR Capital Management increased its Procept Biorobotics (PRCT) stake by 45% in Q2 2026, buying an estimated $2.87M and bringing the position to 370,455 shares worth $8.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

AQR Capital Management first reported a position in PRCT in Q2 2024 and has held it in 9 quarters since. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • AQR Capital Management held 370,455 shares of Procept Biorobotics worth $8.36M as of Q2 2026.
  • AQR Capital Management bought 114,604 Procept Biorobotics shares in Q2 2026, an estimated $2.87M.
  • Procept Biorobotics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1682 holding.
  • AQR Capital Management first reported a position in Procept Biorobotics in Q2 2024 and has held it in 9 quarters since.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.